Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry

Ji-Yeon Kim, MD1; Danbee Kang, PhD2; Seok Jin Nam, MD, PhD1; Seok Won Kim, MD, PhD1; Jeong Eun Lee, MD, PhD1; Jong Han Yu, MD, PhD1; Se Kyung Lee, MD, PhD1; Young-Hyuck Im, MD, PhD1; Jin Seok Ahn, MD, PhD1; Eliseo Guallar, MD, DrPH1,2; Juhee Cho, PhD1,2; and Yeon Hee Park, MD, PhD1

PURPOSE We evaluated the clinical features and outcomes of invasive breast cancer (BC) among different age groups by analyzing a modern BC registry including subtypes and treatment information.

METHODS This was a retrospective cohort study of 6,405 women aged 18 years or older with pathologically confirmed stage I, II, or III BC who underwent curative surgery followed by adjuvant therapy at a university-based hospital in Seoul, South Korea, between January 2003 and December 2011. The study end point was all-cause mortality. We used Cox proportional hazards models and hazard ratios (HRs) with 95% CIs calculated after adjusting for age, body mass index, stage, subtype, and treatment, including type of surgery and use of chemotherapy, radiation therapy, hormone therapy, and targeted therapy.

RESULTS During 36,360 person-years of follow-up (median follow-up: 5.45 years; interquartile range, 4.3-7.1), 256 deaths were reported (mortality rate, 7.0/1,000 person-years). The adjusted HR for all-cause mortality was higher in patients older than 40 years (HR, 2.03; 95% CI, 1.44 to 2.87) and older than 60 years (HR, 2.35; 95% CI, 1.63 to 3.39) than in patients aged 40 to 49 years. Across age groups, advanced stage at diagnosis, luminal type as well as triple-negative BC, and not receiving adjuvant treatment were associated with increased risk of mortality.

CONCLUSION A strong J-shaped relationship was observed between age and mortality, indicating worse clinical outcomes in young and old patients. This study suggested a possible benefit of personalized BC screening examination and precise and active treatment strategies to reduce BC-related mortality.

J Global Oncol. © 2019 by American Society of Clinical Oncology

INTRODUCTION Breast cancer (BC) is the most common type of cancer in women worldwide, with approximately 1,670,000 new cases globally. Although 90% of patients with BC survive for over 5 years, up to 10% of patients experience disease recurrence and die of disease progression after curative surgery. TNM stage, tumor grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status are major predictive markers for recurrence; they have been incorporated into management guidelines and are used to personalize treatment regimens with targeted agents. Moreover, age at diagnosis, alcohol consumption, smoking, and obesity have been associated with prognosis in some studies, but young age at diagnosis was consistently associated with poor prognosis. Most studies of clinical outcomes and prognostic factors of BC have been conducted in Western countries before the introduction of modern tumor subtyping and targeted treatments. Moreover, the results from Western studies may not be applicable to Asian women, because of the major differences in clinical characteristics of BC in these women.

BC is the second most common cancer in Korea after thyroid cancer (crude incidence rate, 72.1 per 100,000 people in 2014). Up to 50% of Korean patients with BC receive the diagnosis before 50 years of age, and most Korean women with BC are premenopausal, one of the risk factors for disease progression and poor clinical outcomes. Some studies have investigated the clinical characteristics and outcomes of Korean patients with BC by age; however, these studies only evaluated a specific age group—either the very young (< 40 years) or very old (> 70 years). In addition, like previous studies in Western countries, they had limited information about subtype and detailed treatments, including hormone or targeted therapy. In this study, we aimed to evaluate the clinical features and outcomes of invasive BC among different age groups by analyzing a large hospital-based BC registry including information on...
modern subtyping and detailed treatment. We specifically hypothesized that the clinical features and outcomes would be different depending on the patient’s age at diagnosis.

METHODS

Study Population

This was a retrospective cohort study of women at least 18 years old with pathologically confirmed stage I, II, or III BC (N = 6,692) who underwent curative surgery followed by adjuvant systemic therapy at Samsung Medical Center, Seoul, Korea, between January 2003 and December 2011. We excluded patients who had missing information on menopausal status (n = 115) or subtype (ER, n = 10; PR, n = 9; and HER2, n = 181). Because study participants could have more than one exclusion criterion, the final sample size was 6,405. The Institutional Review Board of the Samsung Medical Center approved this study and waived the requirement for informed consent because we used only deidentified data routinely collected during clinical care.

Measurements

Detailed information on surgery, adjuvant chemotherapy, radiotherapy, hormone therapy, and targeted therapy were obtained from electronic medical records. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared at the time of BC diagnosis. Women were considered postmenopausal if they were amenorrheic for at least 12 months, had a prior bilateral oophorectomy, or were age 60 years or older.4

Pathologic stage was based on the criteria of the American Joint Committee on Cancer.17 Two pathologists with 13 and 17 years of experience, respectively, reviewed and determined the primary tumor characteristics on the basis of size, axillary nodal status, resection margin, and receptor status (ER, PR, and HER2) by immunohistochemical staining. ER positivity and PR positivity were defined as an Allred score of 3 to 8, on the basis of immunohistochemical staining with antibodies against ER (Immunotech, France) and PR (Novocastra, UK), respectively. HER2 status was evaluated using the appropriate antibody (Dako, Carpinteria, CA) and/or silver in situ hybridization. HER2 grades 0 and 1 indicated a negative result, and grade 3 indicated a positive result. Amplification of HER2 was confirmed by silver in situ hybridization for results of 2+. Triple negative BC (TNBC) was defined as BC with negative ER expression, PR expression, and HER2 overexpression.

The study end point was all-cause mortality. The secondary end point was distant recurrence, including soft tissue or nodal metastases in distant sites, bone metastases, visceral metastases in other organs, and diffuse intra-abdominal metastases.

Statistical Analysis

For all-cause mortality, patients were included in the study at the time of diagnosis and were followed up until death or the end of the study period (May 31, 2016). To determine the clinical features associated with mortality, we used Cox proportional hazards models and hazard ratios (HRs) with 95% CIs calculated after adjusting for age, BMI, stage, subtype, and treatment, including type of surgery and use of chemotherapy, radiation therapy, hormone therapy, and targeted therapy. With regard to distant recurrence, patients were followed until the first recorded evidence of treatment failure or until the last follow-up visit for those alive without recurrence. To account for competing risks due to mortality, we fitted a proportional subdistribution hazards regression model using the Fine and Gray regression model18 with death as the competing event. All reported P values were two sided, and the significance level was set at 0.05. Statistical analyses were performed using STATA, version 14 (StataCorp LP, College Station, TX).

RESULTS

The median age at BC diagnosis was 48.6 (interquartile range, 42-54) years; approximately 16.7%, 42.5%, 26.5%, and 14.3% of women were younger than 40 years old, 40 to 49 years old, 50 to 59 years old, and older than 60 years, respectively; and 37.2% of patients were postmenopausal (Table 1). Altogether, 12.7% of patients were diagnosed with stage III BC, and those younger than 40 years were more likely to be diagnosed with stage III (14.6%) than were older patients (P < .001). The proportion of BC subtype was significantly different by age groups: ER+ or PR+ BC and HER2– BC commonly occurred in women in the 40 to 49 years age group (70.1%), whereas ER–, PR–, and HER2– BC (ie, TNBC) commonly occurred in women younger than 40 years (21.6%) (Table 1). In terms of treatment, 72.3%, 75.5%, 98.8%, and 46.7% of patients received chemotherapy, radiation therapy, hormone therapy, and targeted therapy, respectively; and patients older than 60 years were less likely to receive chemotherapy or radiotherapy (Table 1).

After 36,360 person-years of follow-up (median follow-up: 5.45 years; interquartile range, 4.3–7.1), 256 deaths were reported (mortality rate, 7.0 per 1,000 person-years). In the entire follow-up, the cumulative probability of overall survival was consistently lower in participants younger than 40 years and older than 60 years compared with those 40 to 49 years old (Fig 1). In spline regression models, there was a strong J-shaped association between age and mortality (Fig 2). After adjusting for BMI, stage, and treatment including surgery, chemotherapy, and radiotherapy, the HR for all-cause mortality was significantly higher in patients younger than 40 years (HR, 2.03; 95% CI, 1.44 to 2.87) and in patients older than 60 years (HR, 2.35; 95% CI, 1.63 to 3.39) than in those 40 to 49 years old (Table 2).

Obesity was not associated with increased mortality, but underweight was significantly associated with mortality in patients 50 to 59 years old (HR, 4.52; 95% CI, 1.02 to 19.99). Although underweight also increased risk of
mortality in patients older than 60 years (HR, 2.73; 95% CI, 0.59 to 12.49), it was not a statistically significant factor.

Multivariable-adjusted HRs were significantly higher in patients with stage II (HR, 2.83; 95% CI, 1.90 to 4.20) and stage III (HR, 11.06; 95% CI, 7.07 to 17.30) BC than in those with stage I. With regard to subtype, multivariable-adjusted HRs were higher in patients with TNBC (HR, 3.79; 95% CI, 2.84 to 5.06) and ER−, PR−, and HER2+ BC (HR, 2.32; 95% CI, 1.62 to 3.32) than in those with ER+ or PR+ and HER2− BC. The positive association among stage, TNBC, and mortality was consistent in all age groups. Patients who did not receive chemotherapy (HR, 2.13; 95% CI, 1.41 to 3.20), hormone therapy (HR, 5.07; 95% CI, 2.23 to 11.53), and targeted therapy (HR, 1.09; 95% CI, 1.01 to 1.17) were more likely to die than those who received each specific therapy. Especially, among patients older than 60 years, those who did not receive hormone therapy had a 15-times higher risk of dying compared with

### TABLE 1. Characteristics of Study Population

| Characteristic | Overall (N = 6,405) | Age < 40 years (n = 1,070) | Age 40-49 years (n = 2,722) | Age 50-59 years (n = 1,696) | Age ≥ 60 years (n = 917) | P |
|----------------|---------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------|---|
| Age, mean ± SD, years | 48.6 ± 9.9 | 35.1 ± 3.6 | 44.9 ± 2.8 | 53.6 ± 2.8 | 66.1 ± 5.3 | <.001 |
| BMI, kg/m² | 197 (3.1) | 86 (8.1) | 78 (2.9) | 24 (1.4) | 9 (1.0) | <.001 |
| Underweight (< 18.5) | 2,968 (44.8) | 626 (58.5) | 1,392 (51.1) | 650 (38.3) | 200 (21.8) | .006 |
| Normal weight (18.5-23) | 1,500 (23.4) | 192 (17.9) | 638 (23.4) | 460 (27.1) | 210 (22.9) | .006 |
| Overweight (23-25) | 1,840 (28.7) | 166 (15.5) | 614 (22.6) | 562 (33.2) | 492 (54.3) | .006 |
| Obese (> 25) | 2,381 (37.2) | 5 (0.5) | 209 (7.7) | 1,250 (73.7) | 917 (100.0) | <.001 |
| Postmenopausal | 2,381 (37.2) | 5 (0.5) | 209 (7.7) | 1,250 (73.7) | 917 (100.0) | <.001 |
| Stage | 2,872 (44.8) | 426 (39.8) | 1,230 (45.2) | 804 (47.4) | 412 (44.9) | .006 |
| I | 2,717 (42.4) | 488 (45.6) | 1,159 (42.6) | 674 (39.7) | 396 (43.2) | .006 |
| II | 816 (12.7) | 156 (14.6) | 333 (12.2) | 218 (12.9) | 109 (11.9) | .006 |
| Surgery type | 2,037 (31.8) | 384 (35.9) | 834 (30.6) | 498 (29.4) | 321 (35.0) | .006 |
| Mastectomy | 4,368 (68.2) | 686 (64.1) | 1,888 (69.4) | 1,198 (70.6) | 596 (65.0) | .006 |
| Lumpectomy | 2,037 (31.8) | 384 (35.9) | 834 (30.6) | 498 (29.4) | 321 (35.0) | .006 |
| Estrogen receptor | 1,784 (27.8) | 325 (30.4) | 615 (22.6) | 569 (33.5) | 275 (30.0) | .006 |
| Negative | 4,621 (72.2) | 745 (69.6) | 2,107 (77.4) | 1,127 (66.5) | 642 (70.0) | .006 |
| Positive | 2,104 (32.8) | 364 (34.0) | 670 (24.6) | 706 (41.6) | 364 (39.7) | .006 |
| Progesterone receptor | 4,301 (67.2) | 706 (66.0) | 2,052 (75.4) | 990 (58.4) | 553 (60.3) | .006 |
| Negative | 5,152 (80.4) | 890 (83.2) | 2,291 (84.2) | 1,231 (72.6) | 740 (80.7) | .006 |
| Positive | 4,633 (72.3) | 852 (79.6) | 2,037 (74.8) | 1,255 (74.0) | 489 (53.3) | .006 |
| HER2 | 1,253 (19.6) | 180 (16.8) | 431 (15.8) | 465 (27.4) | 177 (19.3) | .006 |
| Negative | 4,113 (64.2) | 659 (61.6) | 1,908 (70.1) | 960 (56.6) | 586 (63.9) | .006 |
| ER or PR+, HER2− | 587 (9.2) | 97 (9.1) | 232 (8.5) | 193 (11.4) | 65 (7.1) | .006 |
| ER and PR−, HER2− | 1,039 (16.2) | 231 (21.6) | 383 (14.1) | 271 (16.0) | 154 (16.8) | .006 |
| ER and PR−, HER2+ | 666 (10.4) | 83 (7.7) | 199 (7.3) | 272 (16.0) | 112 (12.2) | .006 |
| Chemotherapy, yes | 4,633 (72.3) | 852 (79.6) | 2,037 (74.8) | 1,255 (74.0) | 489 (53.3) | <.001 |
| Radiotherapy, yes | 4,637 (75.5) | 772 (72.2) | 2,103 (77.3) | 1,319 (77.8) | 643 (70.1) | <.001 |
| Hormone therapy*, yes | 4,644 (98.8) | 747 (98.8) | 2,123 (99.2) | 1,133 (98.3) | 641 (98.5) | .09 |
| Targeted therapy†, yes | 585 (46.7) | 89 (49.4) | 205 (47.6) | 215 (46.2) | 76 (42.9) | .63 |

NOTE. Data are reported as no. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.
*Among participants who had ER or PR+ (n = 4,700).
†Among participants who had HER2+ (n = 1,253).
patients receiving hormone therapy (HR, 15.49; 95% CI, 4.72 to 50.86; Table 2).

The cumulative distant recurrence rates were consistently higher in participants younger than 40 years (HR, 1.68; 95% CI, 1.29 to 2.18) compared with those 40 to 49 years old (Table 3; Fig 3). In multivariable models with mortality as a competing risk, advanced stage was associated with recurrence in all age groups. Patients with TNBC (HR, 2.24; 95% CI, 1.75 to 2.87) and ER−, PR−, and HER2+ BC (HR, 1.50; 95% CI, 1.09 to 2.06) had higher risk of distant recurrence than those with ER+ or PR+ BC and HER2− BC. Moreover, patients who did not receive hormone therapy had a higher risk of distant recurrence (HR, 2.61; 95% CI, 1.13 to 6.00) than those who received hormone therapy.

**DISCUSSION**

By analyzing this modern BC registry, we found a strong J-shaped association between age and mortality. The HR for all-cause mortality was significantly higher in patients younger than 40 years and older than 60 years than those 40 to 49 years old, after adjusting for all other risk factors. Besides age group, advanced stage at diagnosis, luminal type including TNBC, and not receiving chemotherapy, hormone therapy, and targeted therapy were associated with all-cause mortality. Different clinical features were associated with increased risk of all-cause mortality and distant recurrence, depending on age groups.

In all age groups, advanced cancer stage was significantly associated with all-cause mortality and distant recurrence, emphasizing the importance of BC screening and early detection. There was clear evidence that regular screening can help detect early-stage cancer and screening examination provides a significant decrease (20% to 35%) in BC mortality. In our study, patients younger than 40 years were more likely to be diagnosed with stage III BC than were older patients, resulting in relatively higher mortality. In Korea, like most other countries, BC screening is provided to women older than 40 years. Therefore, women younger than 40 years would have less chance of undergoing BC screening such as mammography or breast ultrasonography than older patients who were recommended for routine screening. In fact, many women at an average risk of BC are offered relatively little opportunity to discuss and initiate mammographic screening before the age of 50 years. Although regular screening or clinical examination of women younger than 40 years remains controversial, personalized approaches to BC screening have been discussed. Now a clinical trial in the United States is examining efficacy of screening patients at an earlier age, regular performance of mammograms, and continuation of screening until women are older, on the basis of a model including personal history, family history, and genetic testing. It would be necessary to conduct similar trials with Asian women, considering that their clinical features are different from those of Western women. In our study, the proportion of patients with stage I BC who were older than 60 years was relatively small, which might be associated with the higher mortality observed in individuals that age group. Previous studies found that patients 60 to 69 years old were 0.61 times less likely to undergo screening mammography than those 40 to 49 years old. Although we did not have screening information, the lower proportion of patients with stage I BC who were older than 60 years might be due to the lower screening rate. Older women should be encouraged to undergo regular screening for the early detection of cancer.
which would facilitate early treatment and improvement of prognosis.

Beside advanced stage at diagnosis, young patients with BC had worse clinical outcomes, partly because of the over-representation of more aggressive subtypes such as TNBC or HER2+ BC. In fact, in our study, higher proportions of women with stage II and III BC and TNBC were younger than 40 years. Considering that patients with TNBC who were from other age groups had a higher mortality rate than those with other subtypes, patients younger than 40 years

| Characteristic | Overall | Age < 40 Years | Age 40-49 Years | Age 50-59 Years | Age ≥ 60 Years |
|---------------|---------|----------------|----------------|----------------|---------------|
| Age, years    | 1.01 (1.00 to 1.03) | 0.96 (0.90 to 1.03) | 1.05 (0.96 to 1.15) | 1.08 (0.99 to 1.18) | 1.06 (1.01 to 1.11) |
| Age group, years |         |                |                |                |               |
| < 40          | 2.03 (1.44 to 2.87) |                |                |                |               |
| 40-49         | Ref.                |                |                |                |               |
| 50-59         | 1.34 (0.94 to 1.89) |                |                |                |               |
| > 60          | 2.35 (1.63 to 3.39) |                |                |                |               |
| BMI, kg/m²    |         |                |                |                |               |
| Underweight (< 18.5) | 1.44 (0.70 to 2.98) | 0.88 (0.31 to 2.52) | —              | 4.52 (1.02 to 19.99) | 2.73 (0.59 to 12.49) |
| Normal weight (18.5-23) | Ref. | Ref. | Ref. | Ref. | Ref. |
| Overweight (23-25) | 0.80 (0.57 to 1.13) | 1.00 (0.52 to 1.95) | 0.94 (0.51 to 1.72) | 0.77 (0.38 to 1.57) | 0.60 (0.25 to 1.47) |
| Obese (> 25)  | 1.14 (0.85 to 1.52) | 1.25 (0.65 to 2.43) | 1.23 (0.70 to 2.15) | 0.99 (0.56 to 1.79) | 1.05 (0.58 to 1.93) |
| Stage         |         |                |                |                |               |
| I             | 2.83 (1.90 to 4.20) | 1.34 (0.64 to 2.80) | 2.19 (0.96 to 5.00) | 2.41 (0.99 to 5.83) | 3.72 (1.81 to 7.65) |
| II            | 11.06 (7.07 to 17.30) | 5.65 (2.30 to 13.89) | 8.55 (3.41 to 21.43) | 16.79 (6.71 to 42.01) | 6.41 (2.56 to 16.08) |
| III           | 2.32 (1.62 to 3.32) | 2.77 (1.36 to 5.61) | 4.17 (1.96 to 8.88) | 1.56 (0.72 to 3.37) | 1.95 (0.97 to 3.94) |
| Surgery type  |         |                |                |                |               |
| Mastectomy    | 0.93 (0.65 to 1.33) | 1.08 (0.50 to 2.31) | 0.63 (0.32 to 1.25) | 1.54 (0.74 to 3.18) | 0.93 (0.42 to 2.04) |
| Lumpectomy    | Ref. | Ref. | Ref. | Ref. | Ref. |
| Subtype       |         |                |                |                |               |
| ER or PR+, HER2− | Ref. | Ref. | Ref. | Ref. | Ref. |
| ER or PR+, HER2+ | 0.86 (0.49 to 1.50) | 1.34 (0.55 to 3.23) | 0.95 (0.28 to 3.17) | 0.89 (0.30 to 2.62) | 0.26 (0.04 to 1.91) |
| ER and PR−, HER2− | 3.79 (2.84 to 5.06) | 1.41 (0.74 to 2.71) | 7.80 (4.50 to 13.53) | 5.56 (3.00 to 10.30) | 1.95 (1.05 to 3.62) |
| ER and PR−, HER2+ | 2.32 (1.62 to 3.32) | 2.77 (1.36 to 5.61) | 4.17 (1.96 to 8.88) | 1.56 (0.72 to 3.37) | 1.95 (0.97 to 3.94) |
| Chemotherapy  |         |                |                |                |               |
| Yes           | 2.13 (1.41 to 3.20) | 1.00 (0.40 to 2.54) | 0.88 (0.27 to 2.87) | 2.45 (0.90 to 6.73) | 1.62 (0.80 to 3.28) |
| No            | Ref. | Ref. | Ref. | Ref. | Ref. |
| Radiotherapy  |         |                |                |                |               |
| Yes           | 1.22 (0.80 to 1.87) | 1.00 (0.39 to 2.56) | 1.00 (0.43 to 2.35) | 2.00 (0.79 to 5.05) | 1.08 (0.48 to 2.47) |
| No            | Ref. | Ref. | Ref. | Ref. | Ref. |
| Hormone therapy* |     |                |                |                |               |
| Yes           | 5.07 (2.23 to 11.53) | 2.40 (0.29 to 19.57) | 5.28 (0.59 to 47.18) | 1.99 (0.18 to 22.28) | 15.49 (4.72 to 50.86) |
| No            | Ref. | Ref. | Ref. | Ref. | Ref. |
| Targeted therapy† | |                |                |                |               |
| Yes           | 1.09 (1.01 to 1.17) | 1.05 (0.91 to 1.20) | 1.16 (0.97 to 1.38) | 1.11 (0.95 to 1.30) | 1.15 (0.96 to 1.38) |
| No            | Ref. | Ref. | Ref. | Ref. | Ref. |

NOTE. Data reported as hazard ratio (95% CI). Model was adjusted for age, BMI, stage, subtype, and treatment including type of surgery, chemotherapy, and radiotherapy.

Abbreviations: —, no data; BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; Ref., reference.

*Among participants who had ER or PR+ disease (n = 4,700).
† Among participants who had HER2+ disease (n = 1,253).
might have poor prognosis regardless of the subtype. This finding was also consistent with the results of the previous studies. A cohort study of patients with newly diagnosed BC from one of eight National Comprehensive Cancer Network centers in the United States found that progression of TNBC did not differ according to age group. However, patients with luminal BC who were younger than 40 years had higher risk of BC-specific mortality than patients in

| Characteristic                  | Overall   | Age < 40  | Aged 40-49 | Aged 50-59 | Age ≥ 60 |
|--------------------------------|-----------|-----------|------------|------------|----------|
| Age, years                     | 0.99 (0.98 to 1.00) | 0.93 (0.88 to 0.97) | 1.02 (0.96 to 1.08) | 1.02 (0.96 to 1.10) | 1.02 (0.97 to 1.08) |
| Age groups, years              |           |           |            |            |          |
| < 40                           | 1.68 (1.29 to 2.18) |               |            |            |          |
| 40-49                          | Ref.      |           |            |            |          |
| 50-59                          | 1.06 (0.80 to 1.40) |               |            |            |          |
| > 60                           | 1.31 (0.96 to 1.80) |               |            |            |          |
| BMI, kg/m²                     |           |           |            |            |          |
| Underweight (< 18.5)           | 1.29 (0.75 to 2.22) | 0.97 (0.48 to 1.97) | 1.35 (0.46 to 3.96) | 1.06 (0.13 to 8.393) | 0.84 (0.06 to 10.96) |
| Normal weight (18.5-23)        | Ref.      | Ref.      | Ref.       | Ref.       | Ref.     |
| Overweight (23-25)             | 1.01 (0.75 to 2.22) | 0.95 (0.54 to 1.69) | 1.24 (0.82 to 1.88) | 0.92 (0.55 to 1.56) | 0.81 (0.34 to 1.92) |
| Obese (> 25)                   | 1.08 (0.85 to 1.37) | 1.07 (0.63 to 1.80) | 1.20 (0.78 to 1.82) | 0.76 (0.46 to 1.27) | 1.33 (0.71 to 2.48) |
| Stage                          |           |           |            |            |          |
| I                              | 2.42 (1.70 to 3.44) | 1.78 (0.98 to 3.23) | 2.52 (1.29 to 4.91) | 1.83 (0.96 to 3.50) | 3.40 (1.38 to 8.37) |
| II                             | 8.89 (6.02 to 13.11) | 6.61 (3.04 to 14.40) | 8.94 (4.41 to 18.15) | 8.27 (4.09 to 16.72) | 7.90 (2.82 to 22.15) |
| Surgery type                   |           |           |            |            |          |
| Mastectomy                     | 0.84 (0.62 to 1.14) | 0.79 (0.37 to 1.69) | 0.72 (0.44 to 1.18) | 1.25 (0.69 to 2.28) | 0.52 (0.26 to 1.05) |
| Lumpectomy                     |           |           |            |            |          |
| Subtype                        |           |           |            |            |          |
| ER or PR+, HER2−               | 1.32 (0.93 to 2.85) | 0.84 (0.48 to 1.46) | 1.33 (0.72 to 2.46) | 1.92 (1.04 to 3.53) | 1.24 (0.45 to 3.38) |
| ER or PR+, HER2+               | Ref.      | Ref.      | Ref.       | Ref.       | Ref.     |
| ER and PR−, HER2−              | 2.24 (1.75 to 2.87) | 1.64 (0.88 to 3.09) | 3.42 (2.29 to 5.10) | 2.59 (1.49 to 4.50) | 2.28 (1.21 to 4.30) |
| ER and PR−, HER2+              | 1.50 (1.09 to 2.06) | 1.64 (0.88 to 3.09) | 2.20 (1.25 to 3.86) | 1.08 (0.57 to 2.07) | 1.20 (0.50 to 2.85) |
| Chemotherapy                   |           |           |            |            |          |
| Yes                            | 1.11 (0.74 to 1.66) | 0.68 (0.30 to 1.54) | 0.94 (0.40 to 2.23) | 0.79 (0.32 to 1.94) | 1.18 (0.51 to 2.74) |
| No                             |           |           |            |            |          |
| Radiotherapy                   |           |           |            |            |          |
| Yes                            | 1.25 (0.87 to 1.79) | 1.29 (0.55 to 3.02) | 1.44 (0.80 to 2.23) | 1.35 (0.64 to 2.82) | 0.65 (0.29 to 1.44) |
| No                             |           |           |            |            |          |
| Hormone therapy*               |           |           |            |            |          |
| Yes                            | 2.61 (1.13 to 6.00) | 2.52 (0.25 to 25.81) | 7.23 (2.31 to 22.61) | 0.83 (0.07 to 9.74) | 2.21 (0.37 to 13.08) |
| No                             |           |           |            |            |          |
| Targeted therapy†              |           |           |            |            |          |
| Yes                            | 1.54 (0.94 to 2.50) | 1.74 (0.74 to 4.06) | 1.75 (0.69 to 4.47) | 0.96 (0.39 to 2.35) | 4.74 (0.55 to 40.78) |
| No                             |           |           |            |            |          |

NOTE. Model adjusted for age, BMI, stage, subtype, and treatment, including type of surgery, chemotherapy, and radiotherapy. Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; Ref., reference.

*Among participants who had ER or PR+ disease (n = 4,700).
†Among participants who had HER2+ disease (n = 1,253).
This hormone therapy. Among the patients with HER2+ BC, those who did not receive targeted therapy had worse progression than those who did. These findings are consistent with those of previous studies. Many studies already demonstrated that adjuvant treatment is effective in improving survival. In our study, a substantially less proportion of patients older than 60 years than younger patients received chemotherapeutic and radiation therapy, and patients who did not receive hormone therapy had a 15-times higher risk of mortality than patients who did. Traditionally, the cutoff age of 65 years was considered to define elderly patients, who are considered vulnerable to standard adjuvant chemotherapy. According to a previous study, physicians were less likely to treat elderly women with adjuvant therapy after curative surgery, and older patients might be less likely to receive adjuvant therapy because they do not feel the necessity of additional treatment or because they have concerns about potential adverse effects. In fact, treatment-related symptoms are also a frequent reason for discontinuing therapy (20%). Older patients might be less likely to receive adjuvant therapy considering the potential adverse effects, resulting in poor progression. However, age should not be used as the sole criterion in deciding a therapeutic regimen for patients with BC. Instead, the estimated absolute benefit, life expectancy, tolerance, and performance of each patient should be considered. Meanwhile, all therapeutic regimens may need to be adapted for the elderly patients to minimize toxicity and achieve favorable long-term outcomes. Moreover, patients need to be informed about possible benefits of adjuvant therapy and hormonal therapies. Provision of education and supportive care would also be meaningful for elderly patients to comply with planned therapy.

The current study had some limitations. First, behavioral risk factors associated with outcomes such as smoking, drinking, and exercise were not evaluated. Second, although we had relatively larger sample size compared with those of previous studies, we still had limited power to evaluate the risk factors in each age group. Third, because the registry was from a single institution in Seoul, Korea, the characteristics of study patients would be different from those at other institutions or other countries. Hence, the results of our study might not be generalizable to other patients with cancer in other settings. Despite these limitations, this is the first comprehensive modern registry to include all subtypes and treatment information, presenting valuable information on the clinical characteristics and outcomes of patients with BC by age groups.

Altogether, we confirmed a strong J-shaped association between age and mortality, presenting worse clinical outcomes of young and old patients. We also confirmed the impact of stage at diagnosis, subtype, and adjuvant treatment on outcomes of BC regardless of age. This study suggested a possible benefit of personalized BC.
screening examination and precise and active treatment strategies to reduce BC mortality. Yet, considering that the BC epidemiology in Korea differs from that in Western countries, additional multicenter studies are warranted to develop a more precise treatment guideline by age group.

AFFILIATIONS
1Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

CORRESPONDING AUTHOR
Yeon Hee Park, MD, PhD, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; e-mail: yhparkhm@skku.edu.

EQUAL CONTRIBUTION
J.-Y.K., D.K., and J.C. contributed equally to this work.

SUPPORT
Supported by the National Research Foundation of Korea (Grants No. NRF-2018R1AZB6004690 and NRF-2017R1D1A1B03028446); the Ministry of Health and Welfare, Republic of Korea (Grant No. HA17C0055); and the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (Grant No. 1720150).

AUTHOR CONTRIBUTIONS
Conception and design: Seok Jin Nam, Eliseo Guallar, Juhee Cho, Yeon Hee Park
Administrative support: Juhee Cho
Provision of study material or patients: Ji-Yeon Kim, Seok Jin Nam, Seok Won Kim, Jeong Eun Lee, Jong Han Yu, Se Kyung Lee, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park
Collection and assembly of data: Ji-Yeon Kim, Danbee Kang, Juhee Cho, Yeon Hee Park

REFERENCES
1. Ferlay J, Siegel R, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [Internet]. International Agency for Research on Cancer. Lyon, France. 2013.
2. Kohler BA, Sherman RL, Howlader N, et al: Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107:dx048, 2015
3. Edwards BK, Noone AM, Mariotto AB, et al: Annual report to the nation on the status of cancer, 1975-2011, featuring survival of colorectal, breast, or prostate cancer. Cancer 120:1290-1314, 2014
4. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer Version 3.2016. Plymouth Meeting, PA, National Comprehensive Cancer Network, 2016
5. Adami HO, Maiker B, Holmberg L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559-563, 1986
6. Smith-Warner SA, Spiegelman D, Yaun SS, et al: Alcohol and breast cancer in women: A pooled analysis of cohort studies. JAMA 279:535-540, 1998
7. Reynolds P, Hurley S, Goldberg DE, et al: Active smoking, household passive smoking, and breast cancer: Evidence from the California Teachers Study. J Natl Cancer Inst 96:29-37, 2004
8. Chan DS, Vieira AR, Aune D, et al: Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901-1914, 2014
9. Ahn Sh, Sohn BH, Kim SW, et al: Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea–A report from the Korean Breast Cancer society. J Clin Oncol 25:2360-2368, 2007
10. Lee JY, Lim SH, Lee MY, et al: Impact on survival of regular postoperative surveillance for patients with early breast cancer. Cancer Res Treat 47:765-773, 2015
11. Jung K-W, Won Y-J, Oh C-M, et al: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49:292-305, 2017
12. DeRouen MC, Gomez SL, Press DJ, et al: A population-based observational study of first-course treatment and survival for adolescent and young adult females with breast cancer. J Adolesc Young Adult Oncol 2:95-103, 2013
13. Kaplan HG, Malmgren JA, Atwood MK: Triple-negative breast cancer in the elderly: Prognosis and treatment. Breast J 23:630-637, 2017
14. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
15. Spitala A, Mazzola P, Soldini D, et al: Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628-635, 2009

Data analysis and interpretation: Ji-Yeon Kim, Danbee Kang, Eliseo Guallar, Juhee Cho, Yeon Hee Park
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jgo/site/misc/authors.html.

Jong Han Yu
Research Funding: Alvogen Korea (Inst)

Jin Seok Ahn
Honoraria: Menarini, Amgen, Pfizer, AstraZeneca, Roche, Janssen, MSD, Bristol-Myers Squibb-Ono Pharmaceutical, Eisai, Boehringer Ingelheim
Consulting or Advisory Role: Samsung Bioepis

Yeon Hee Park
Honoraria: Novartis, Pfizer, Merck
Consulting or Advisory Role: Pfizer
Research Funding: AstraZeneca, Pfizer, Eisai
Travel, Accommodations, Expenses: Merck, Novartis

No other potential conflicts of interest were reported.

No other potential conflicts of interest were reported.

No other potential conflicts of interest were reported.
16. Lee W-S, Lee JE, Kim JH, et al: Analysis of prognostic factors and treatment modality changes in breast cancer: A single institution study in Korea. Yonsei Med J 48:465-473, 2007
17. Edge SB BD, Compton CC, Fritz AG, et al (eds): AJCC Cancer Staging Manual, 7th ed. Paris, France, Springer, 2010
18. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc: 94:496-509, 1999
19. Choi KS, Yoon M, Song SH, et al: Effect of mammography screening on stage at breast cancer diagnosis: Results from the Korea National Cancer Screening Program. Sci Rep 8:8882, 2018
20. Fletcher SW, Elmore JG: Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348:1672-1680, 2003
21. Bevers TB, Helvie M, Bonaccio E, et al: Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:1362-1389, 2018
22. Korean Breast Cancer Society: Breast Cancer Facts & Figures 2018. Seoul, Korea, 2018
23. Smith P, Hum S, Kakzanov V, et al: Physicians' attitudes and behaviour toward screening mammography in women 40 to 49 years of age. Can Fam Physician 58:658-6513, 2012
24. Darabi H, Czege K, Zhao W, et al: Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25, 2012
25. Lee K, Lim HT, Park SM: Factors associated with the use of breast cancer screening services by women aged ≥40 years in Korea: The Third Korean National Health and Nutrition Examination Survey 2005 (KNHANES III). BMC Cancer 10:144, 2010
26. Assi HA, Khoury KE, Dbouk H, et al: Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5:S2-S8, 2013 (Suppl 1)
27. Partridge AH, Hughes ME, Warner ET, et al: Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 34:3308-3314, 2016
28. Johansson ALV, Trewin CB, Hjerkild KV, et al: Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144:1251-1261, 2019
29. Kan Z, Ding Y, Kim J, et al: Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun 9:1725, 2018
30. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111-121, 2018
31. Francis PA, Regan MM, Fleming GF, et al: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436-446, 2015
32. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717, 2005
33. Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156-166, 2010
34. Bergman L, Kluck HM, van Leeuwen FE, et al: The influence of age on treatment choice and survival of elderly breast cancer patients in South-Eastern Netherlands: A population-based study. Eur J Cancer 28A:1475-1480, 1992
35. Fink AK, Gunwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004
36. Grunfeld EA, Hunter MS, Sikka P, et al: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97-102, 2005
37. Khan OJ, O’Dea AP, Sharma P: Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol 2010:Article ID 654348, 2010
38. Howlader N, Noone AM, Krapcho M, (eds): SEER Cancer Statistics Review, 1975-2012. 2014. National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2012/
39. Canadian Cancer Society: Statistics Canada and Provincial/Territorial Cancer Registry. Canadian Cancer Statistics 2014.